Mereo BioPharma (MREO) Change in Account Payables (2023 - 2026)
Mereo BioPharma (MREO) posted quarterly Change in Account Payables of $2.0 million for Q1 2026, up 440.61% year-over-year from $362000.0 in Q1 2025, and up 337.81% quarter-over-quarter from $447000.0 in Q4 2025.
Mereo BioPharma (MREO) Change in Account Payables (2023 - 2026) Analysis & Trends
Mereo BioPharma (MREO) has reported Change in Account Payables for 4 consecutive years, with $2.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Account Payables rose 440.61% year-over-year to $2.0 million; the TTM figure through Mar 2026 stood at $217000.0 (down 43.04% YoY), while the FY2025 annual figure was -$1.4 million, down 1043.84% from the prior year.
- Change in Account Payables advanced to $2.0 million in Q1 2026 per MREO's latest filing, from $447000.0 in the prior quarter.
- Across five years, Change in Account Payables topped out at $2.0 million in Q1 2026 and bottomed at -$2.3 million in Q2 2023.
- Historically, Change in Account Payables has averaged -$41384.6 across 4 years, with a median of $241000.0 in 2024.
- Annual changes were most pronounced in 2025 — Change in Account Payables plunged 909.54% — and 2026, when it jumped 440.61%.
- Mereo BioPharma's Change in Account Payables stood at $987000.0 in 2023, then retreated by 14.59% to $843000.0 in 2024, then tumbled by 46.98% to $447000.0 in 2025, then jumped by 337.81% to $2.0 million in 2026.
- Business Quant data shows MREO's Change in Account Payables at $2.0 million in Q1 2026, $447000.0 in Q4 2025, and -$236000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -8.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 37.53 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Mereo BioPharma | 47.39 Mn | 47.39 Mn | - | -2.14 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -2.14 Mn |
| Jun 30, 2026 | -2.14 Mn |
| Mar 31, 2026 | 1.96 Mn |
| Mar 31, 2026 | 1.96 Mn |
| Dec 31, 2025 | 447,000.00 |
| Dec 31, 2025 | 447,000.00 |
| Sep 30, 2025 | -236,000.00 |
| Sep 30, 2025 | -236,000.00 |
| Jun 30, 2025 | -1.95 Mn |
| Jun 30, 2025 | -1.95 Mn |
| Mar 31, 2025 | 362,000.00 |
| Mar 31, 2025 | 362,000.00 |
| Dec 31, 2024 | 843,000.00 |
| Dec 31, 2024 | 843,000.00 |
| Sep 30, 2024 | -1.07 Mn |
| Sep 30, 2024 | -1.07 Mn |
| Jun 30, 2024 | 241,000.00 |
| Jun 30, 2024 | 241,000.00 |
| Mar 31, 2024 | 127,000.00 |
| Mar 31, 2024 | 127,000.00 |